Zydus Lifesciences through its wholly owned subsidiary, and Perfect Day Inc., a Temasek portfolio company (Perfect Day) have signed an agreement wherein Perfect Day will sell its ~50% shareholding in Sterling Biotech (SBL). Post this transaction, Sterling Biotech will become a 50:50 Joint Venture (JV) with equal representation on the Board. The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets. The JV will accelerate the production of high-quality and ecofriendly protein products, reduce environmental impact, and cater to the growing consumer demand for fermentation-based and ethically sourced nutrition. This partnership marks a significant step forward in the global effort to transform the food industry and promote a healthier planet. The acquisition will also mark Zydus` foray into specialised biotech products for health and nutrition, specifically catering to consumers who prefer animal-free protein or suffer from lactose intolerance. Perfect Day`s precision-fermented protein is found in ice creams, cream cheese, sports nutrition products, and baked goods with high functionality benefits and lower environmental impact. This transaction between Perfect Day and Zydus underlines the importance of the emerging global markets for environmentally friendly and sustainable products. Perfect Day will significantly enhance its technological capabilities in India as part of its emerging market growth strategy, while Zydus will continue to leverage its strong manufacturing and commercial expertise. Through this manufacturing partnership both the parties reaffirm their commitment of making India a bright spot in global supply chain. SBL is currently engaged in manufacturing and selling of fermentation-based API products and gelatine. With a clear vision of focussing on animal free protein products the JV partners will also take a strategic view on API and gelatine business.Powered by Capital Market - Live News

Net profit of Zydus Lifesciences rose 30.64% to Rs 1419.90 crore in the quarter ended June 2024 as against Rs 1086.90 crore during the previous quarter ended June 2023. Sales rose 19.67% to Rs 6046.50 crore in the quarter ended June 2024 as against Rs 5052.80 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales6046.505052.80 20 OPM %34.4729.79 - PBDT2115.001523.20 39 PBT1899.701343.40 41 NP1419.901086.90 31 Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Valbenazine Capsules, 40 mg, 60 mg, and 80 mg (USRLD: Ingrezza� Capsules). Valbenazine Capsules are indicated for the treatment of adults with tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts). The drug will be manufactured at the group`s formulation manufacturing facility in Ahmedabad SEZ - II, India. Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Valbenazine Capsules, 40 mg, and 80 mg, and was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Valbenazine Capsules, 60 mg. With this approval, Zydus is eligible for 180 days of shared generic drug exclusivity for Valbenazine Capsules, 40 mg, and 80 mg, and is eligible for 180 days of sole generic drug exclusivity for Valbenazine Capsules, 60 mg. Valbenazine Capsules had annual sales of USD 1993.6 mn in the United States (IQVIA MAT June 2024). Powered by Capital Market - Live News

Zydus Lifesciences announced that the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for Mamitra™, a Trastuzumab biosimilar. The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2 overexpressing metastatic breast cancer (MBC), HER2 overexpressing early breast cancer (EBC) and advanced gastric cancer. Breast cancer has become the most diagnosed cancer in Mexico, overtaking prostate and colorectal cancers.Zydus had developed and launched the Trastuzumab biosimilar developed in-house by the research team at the Zydus Research Centre (ZRC) in 2016 in India under the brand name Vivitra.  Since then, an estimated 1,00,000 patients have been treated with the therapy. With twelve lifesaving biosimilars already launched in the market, Zydus has been bridging the unmet need for affordable therapies in the fight against cancer in India.Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg (USRLD: Diovan� tablets). Valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure in adults and paediatric patients one year of age and older. It is also used in adults to treat heart failure (a condition in which the heart is unable to pump enough blood to the rest of the body) and to improve survival after a heart attack. The drug will be manufactured at the group`s formulation manufacturing facility in Ahmedabad SEZ - II, India.Powered by Capital Market - Live News